摘要目的 分析卡马西平治疗前庭阵发症的有效性和安全性. 方法 选取2013年6月至2017年6月我院神经内科收治的前庭阵发症患者 82例,根据用药不同将其分为卡马西平组(CBZ)31例、卡马西平+倍他司汀组(CBZ+BM T )26例和奥卡西平+倍他司汀组(OXC+BM T )25例.用药3个月后比较3组患者临床疗效、发作频率、眩晕程度及不良反应. 结果 CBZ组治愈14例、好转13例,治疗有效率为87.1%(27/31) ;CBZ+BMT组治愈18例、好转7例,治疗有效率为96.2%(25/26) ;OXC+BM T组治愈15例、好转8例,治疗有效率为92.0%(23/25 ) ;3组治疗有效率差异无统计学意义(χ2＝0.783 ,P＝0.129) .用药治疗3个月后,3组患者中CBZ+BM T组发作频率和眩晕程度最低,CBZ组发作频率和眩晕程度最高(均 P＜0.05) . CBZ组共发生不良反应16例,占51.6%;CBZ+BM T组发生不良反应8例,占30.8%;OXC+BM T组发生不良反应4例,占16.0%. 结论 卡马西平与奥卡西平治疗前庭阵发症疗效相似,联合倍他司汀疗效显著,且安全可靠.

abstractsObjective To evaluate the efficacy and safety of Carbamazepin (CBZ)compared with Oxcarbazepine (OXC ) therapy for vestibular paroxysmia. Methods Eighty-two patients with vestibular paroxysmia were admitted during June 2013 and June 2017 in this study. According to the agents administered ,all patients were divided into the CBZ group(n＝ 31) ,CBZ+ Betahistine(BMT) group(n＝ 26)and OXC+ BMT group(n＝ 25).The clinical efficacy ,frequency ,vertigo and adverse reactions of three groups were compared after 3 months follow-up. Results In CBZ group ,14 cases were cured ,13 were improved ,and the effective rate was 87.1%.In CBZ+BMT group ,18 cases were cured ,7 were recovered ,and the effective rate was 96.2%.In OXC+BMT group ,15 cases were cured , 8 cases were recovered ,and the effective rate was 92.0% . There was no significantly difference in effective rate among the three groups(χ2＝0.783 ,P＝0.129).Meanwhile ,the CBZ+BMT group had the lowest frequency of vestibular paroxysmia and vertigo degree ,while the CBZ group was the highest ;the difference in the frequency and vertigo degree between groups was statistically significant (P＜ 0.05).Furthermore ,the incidences of side-effects were 51.6%(n＝ 16) ,30.8%(n ＝ 8)and 16.0%(n＝4)in the CBZ group ,CBZ+BMT group and OXC+BMT group ,respectively. Conclusions The effect of Carbamazepine and Oxcarbazepine for vestibular paroxysmia is similar ,and is safely and significantly improved when combined with Betahistine.